GABRA2
ENSG00000151834
Target class
Ion channel
Chromosome
4
Approved drugs
56
Clinical candidates (approved and in development)
70
- Approved drugs
- 56
- Clinical candidates (approved and in development)
- 70
- Chemical probe available
- No
- Target name
- GABRA2
- Gene name
- Gamma-aminobutyric acid type A receptor subunit alpha2
- Gene symbol
- GABRA2
- Protein name
- Gamma-aminobutyric acid receptor subunit alpha-2 (GABA(A) receptor subunit alpha-2) (GABAAR subunit alpha-2)
- Gene biotype
- Protein coding
- Gene family
- Gamma-aminobutyric acid type A receptor subunits
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 14
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 11.93
- Tissue specificity (Gini)
- 0.767
- Tissue specificity (tau)
- 0.858
- KEGG gene identifiers
- hsa:2555
- Reactome pathways
- R-HSA-977443
- Protein interaction confidence
- 0.7925
- Protein interaction partners
- 18
- End position
- 46475230
- Start position
- 46243548
- Chromosome
- 4
- Strand
- Reverse
- Postsynaptic cell membrane
- Multi-pass membrane protein . Cell membrane
- Multi-pass membrane protein . Cytoplasmic vesicle membrane . Cell projection, dendrite .
- Nucleoplasm
- Plasma membrane
- Tissue specificity (tau)
- 0.857739
- Expression inequality (Gini)
- 0.766595
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)
- 11.93
- Brain - Nucleus accumbens (basal ganglia)
- 10.74
- Brain - Caudate (basal ganglia)
- 10.68
- Brain - Cortex
- 10.56
- Brain - Anterior cingulate cortex (BA24)
- 10.46
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)11.93
- Brain - Nucleus accumbens (basal ganglia)10.74
- Brain - Caudate (basal ganglia)10.68
- Brain - Cortex10.56
- Brain - Anterior cingulate cortex (BA24)10.46
- Brain - Amygdala8.74
- Brain - Putamen (basal ganglia)7.34
- Brain - Cerebellum5.99
- Brain - Hippocampus4.98
- Brain - Hypothalamus3.29
- Brain - Cerebellar Hemisphere2.97
- Nerve - Tibial2.25
- Kidney - Medulla1.78
- Brain - Substantia nigra1.37
- Brain - Spinal cord (cervical c-1)0.88
- Colon - Transverse0.84
- Small Intestine - Terminal Ileum0.79
- Colon - Sigmoid0.79
- Breast - Mammary Tissue0.6
- Kidney - Cortex0.57
- Adipose - Subcutaneous0.5
- Cervix - Ectocervix0.39
- Cervix - Endocervix0.35
- Vagina0.32
- Artery - Coronary0.26
And 29 more, listed on the interactive page.
- GO:0007214
- GO:1902476
- GO:0005886
- GO:0030672
- GO:1902711
- GO:0005515
- GO:0008503
- GO:0022851
- GO:0099507
- GO:1904315
decreased cardiac contractility
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased cardiac contractility
- central nervous system
- cardiovascular
PubMed 28216264drug abuse/dependence
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: drug abuse/dependence
- central nervous system
- cardiovascular
PubMed 28216264decreased memory
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased memory
- central nervous system
- cardiovascular
PubMed 28216264decreased sleep
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased sleep
- central nervous system
- cardiovascular
PubMed 28216264decreased convulsions
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased convulsions
- central nervous system
- cardiovascular
PubMed 28216264decreased locomotor activity
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased locomotor activity
- central nervous system
- cardiovascular
PubMed 28216264increased eating
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased eating
- central nervous system
- cardiovascular
PubMed 28216264decreased blood pressure
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased blood pressure
- central nervous system
- cardiovascular
PubMed 28216264muscle relaxation
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: muscle relaxation
- central nervous system
- cardiovascular
PubMed 28216264decreased body temperature
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased body temperature
- central nervous system
- cardiovascular
PubMed 28216264decreased pain
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased pain
- central nervous system
- cardiovascular
PubMed 28216264convulsions
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: convulsions
- central nervous system
- cardiovascular
PubMed 28216264decreased anxiety
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased anxiety
- central nervous system
- cardiovascular
PubMed 28216264ataxia
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: ataxia
- central nervous system
- cardiovascular
PubMed 28216264increased respiratory rate
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased respiratory rate
- central nervous system
- cardiovascular
PubMed 28216264increased cardiac output
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased cardiac output
- central nervous system
- cardiovascular
PubMed 28216264increased sleep
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased sleep
- central nervous system
- cardiovascular
PubMed 28216264
Related records
Trials (3,904)
- "Chou's Tiaoshen" Acupoints for Short-term Insomnia.
- "Volatile Anesthetic Protection Of Renal Transplants: VAPOR-1-trail
- (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
- [18F]Fluciclovine in Post-treatment Glioblastoma ( Axumin )
- 1-1-8 Wash-in for Sevoflurane Low Flow Anesthesia
- 12-Month Real-World Safety & Efficacy of Lecanemab in Early Alzheimer's Disease
- 28-day Repeat Dose and Drug Interaction Study With Orvepitant (GW823296)
- 3 mL Inhaled Methoxyflurane for Intrauterine Device (IUD) Insertion
- 50% Effective Concentration of Sevoflurane for Immobility
- 6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia
- A 2-Part Study to Assess Potential Metabolism-Based Drug-Drug Interactions of E2006 When Coadministered With Itraconazole, Rifampin, Midazolam, or Bupropion
- A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder
- A Better Choice for Patients Undergoing Endovascular Coil Embolization
- A Bioequivalence and Food Effect Study of SEP-190 in Japanese Healthy Subjects (Study SEP 190-102)
- A Bioequivalence Study Of A New Alprazolam Dropped Formulation Versus Alprazolam Tablets
- A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone
- A Clinical Study Evaluating Sedation of Intravenous Administration of HSK3486 in ICU Patients Undergoing Long-Term Mechanical Ventilation
- A Clinical Study of Remimazolam Tosilate Compared to Propofol for General Anesthesia During Elective Surgery
- A Clinical Study of Remimazolam Tosilate in Patients Undergoing Bronchoscopy
- A Clinical Study to Assess Next-day Driving Performance Following Administration of ACT-541468 in Middle-aged and Elderly Subjects
Drugs (80)
- ABP-700 GABA-A receptor; anion channel agonist
- Acamprosate GABA-A receptor; anion channel positive modulator
- Acamprosate calcium GABA-A receptor; anion channel positive modulator
- Adipiplon GABA-A receptor; anion channel partial agonist
- Alprazolam GABA-A receptor; anion channel positive allosteric modulator
- AZD6280 GABA receptor alpha-2 subunit positive allosteric modulator
- AZD7325 GABA receptor alpha-2 subunit positive allosteric modulator
- Brexanolone GABA-A receptor; anion channel positive allosteric modulator
- Bromazepam GABA receptor alpha-2 subunit positive allosteric modulator
- Butabarbital GABA-A receptor; anion channel positive allosteric modulator
- Butabarbital sodium GABA-A receptor; anion channel positive allosteric modulator
- Butalbital GABA-A receptor; anion channel positive allosteric modulator
- Cenobamate GABA-A receptor; anion channel positive allosteric modulator
- Chlordiazepoxide GABA-A receptor; anion channel positive allosteric modulator
- Chlordiazepoxide hydrochloride GABA-A receptor; anion channel positive allosteric modulator
- Cipepofol GABA-A receptor; anion channel agonist
- Clobazam GABA-A receptor; anion channel positive allosteric modulator
- Clomethiazole GABA-A receptor; anion channel positive allosteric modulator
- Clonazepam GABA-A receptor; anion channel positive allosteric modulator
- Clorazepate dipotassium GABA-A receptor; anion channel positive allosteric modulator